Status: Recruiting
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
Small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to offer to more patients the possibility of benefiting from an intensification of chemotherapy, which is a major prognostic factor in this population.
Participants needed: 27
Trial details
Phase: Phase 2Age: 12+Biological sex: FemaleType: InterventionalSponsor: ARCAGY/ GINECO GROUPUpdated: Nov 28, 2025Locations: 13
Eligibility criteria
Patient who are at least 12 years of age on the day of signing informed consent... [+17]
Prior therapy for the disease with chemotherapy and/or an anti-PD-1, anti-PD-L1,... [+18]